Romidepsin for cutaneous T-cell lymphoma

Clinical Cancer Research, 05/02/2012

Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side effect profile.

Print Article Summary Cat 2 CME Report